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Abstract
Metastasis, resistance to chemo- and radiotherapy, and eventual relapse has been
attributed to a tumor subpopulation known as cancer stem cells (CSCs). CSCs are
regulated in their tumor microenvironment by various factors. Synthetic hydrogels can
be used to investigate the effects of individual environmental factors on CSCs by
providing inert 3D matrices. In this thesis, poly ethylene glycol diacrylate (PEGDA)
hydrogel with 5kpa modulus has been used as a culture system to study the effect of; I)
integrin and heparin binding peptides, 2) pH, and 3) the shape of the microenvironment
on breast CSCs maintenance and tumorsphere formation in PEGDA. Human breast
cancer cells were encapsulated in PEGDA hydrogels and the effect of the peptides, pH,
and the shape of the environment on tumorsphere formation was investigated by
fluorescent microscopy, qRT-PCR and DNA content assay.
All peptides including RGD, RYD, IKLLI, LIGRKK, VAPG, WQPPRARI, and SPPRRARV
affected breast cancer cells by reducing their capability of sphere formation. Among
peptides, RGD, RYD, and WQPPRARI were the most effective peptides in reducing
sphere formation of breast CSCs.
Moreover, different shapes of micropatterned PEGDA including circle, square, and
rectangle did not influence CSCs maintenance and behavior in forming tumorsphere.
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Breast CSCs formed spherical tumors regardless of the shape of the micropatterned
PEGDA and had the minimum surface area for a given volume. Furthermore, breast CSCs
showed more resistance to acidic pH compared to non-stem breast cancer cells and
normal breast epithelial cells.
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Chapter 1
Introduction
Breast cancer is the second leading cause of cancer death in women. About 1 in 8 (12%)
women in the US will have invasive breast cancer during their life (American Cancer
Society 2015). Regardless of advancements in diagnosis/treatment of metastatic breast
cancer, the rate of death from this disease remains high. This is due to the fact that, the
available therapies are limited by the existence of therapy-resistant cancer cells. Thus,
metastatic breast cancer is an irrepressible disease by current treatment approaches.
That means, further investigation needs to be performed on the breast cancer research
area. Therefore, this research has been designed to achieve a better insight about
these therapy-resistant cancer cells (cancer stem cells) behaviors and interactions in
their microenvironment. Hopefully, the collected information will open up a new useful
path toward the eradication of metastatic breast cancer.

1.1. Tumor Heterogeneity
Tumor heterogeneity refers to the existence of different cells within tumors or between
tumors. Tumor cells are different in morphology, metabolism, proliferation, and ability
of metastasis (Marusyk and Polyak 2010). There are two models that explain the tumor
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heterogeneity: “Cancer stem cell” model and “clonal evolution” model (Shackleton et
al. 2009)Cancer Stem Cell (CSC) model: CSCs are a subpopulation of cancer cells that
form tumors. They self-renew and differentiate to other cancer cells, which are not able
to form tumors. The idea that CSCs contribute a small population of cancer cells comes
from this view that if almost all of the cancer cells would proliferate extensively and
metastasize throughout the body, then all of them should be eradicated by available
therapies. In reality, current cancer treatments are truly able to remove most of the
cancer cells in the body, however the observation of cancer relapse illustrates that there
should be a small population of cancer cells left in the body which initiate the disease
later (Reya et al. 2001). CSCs are capable of self-renewing and differentiating. The
heterogeneity that has been observed between differentiated cells refers to differences
between cancer stem cells that they have originated from. The difference between
cancer stem cells usually arise from epigenetic changes simultaneous with natural
selection of advantageous genetic mutated cancer stem cells (Shackleton et al. 2009).
This model proposes that CSCs behave the same as normal stem cells. They undergo
epigenetic changes and differentiate to cells that are phenotypically different and have
limited proliferation. These differentiated cancer cells make the majority of cells in a
tumor (Shackleton et al. 2009).
Cancer stem cell model has been observed in multiple tumor types such as leukemias
(Campbell et al. 2008), breast cancer(Jabbari et al. 2015), and prostate cancer(Alvarado
et al. 2005). In these cancers, only a small population of cancers could form tumor
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spheres in NOD/SCID mice, and also specific markers for these tumorigenic cells have
been identified (Campbell et al. 2008, Jabbari et al. 2015, Alvarado et al. 2005).

1.2. CSCs and Their Microenvironment
Breast cancer stem cells exist in an environment (niche) which is responsible for the
maintenance of specific stem cell properties like self-renewal and remaining in an
undifferentiated state. The population in niche contains both stem cells and surrounding
differentiated cells. Biochemical signals that breast cancer stem cells get from the
interaction with ECM components and neighbor cells have critical roles in maintenance
of them. Cancer stem cells niche is responsible for the control of the essential pathways
that have critical roles in determination of stem cells destiny. Critical pathways such as
STAT, Notch, and Wnt have been recognized in CSCs niche while some features of
cancers like hypoxia and angiogenesis regulate these pathways. Investigating on
processes within breast CSCs niche can provide a better understanding of these CSCs for
prevention and treatment of metastasis breast cancer.

1.3.

CSC microenvironment and peptides

The extracellular matrix (ECM) is a collection of extracellular molecules secreted by cells
that provide structural and biochemical support to the surrounding cells. Cell adhesion,
and cell-to-cell communication are common functions of the ECM (Abedin and King
2010).
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Fibronectin, laminin and elastin are 3 components of ECM. These proteins which are
long chains of amino acids, and peptides derived from these proteins which are short
chains of amino acids are well known for mediating cell adhesion. It has been shown
that the occurrence of breast cancer is concurrent with changes in these proteins
expression, degradation and expression of their binding receptors.
VAPG (derived from elastin), IKLLI (derived from laminin), RYD (derived from
streptavidin), and RGD (derived from fibronectin) are integrin binding peptides and
WQPPRRARI and SPPRRARV (derived from fibronectin) are heparin binding peptides.
Integrins and heparan sulfate proteoglycans are receptors that play critical roles in
development of metastasis breast cancer as they activate focal adhesions mainly focal
adhesion kinase (FAK). FAK is an intracellular non-receptor tyrosine kinase. It has been
shown that FAK is highly overexpressed in breast cancers and it has key roles in
promoting tumorigenesis and metastasis (Luo and Guan 2010).
Therefore, we chose these cell binding peptides from different domains of these
proteins to investigate their effects on breast cancer stem cells maintenance in PEGDA.
The importance of using peptides over proteins is due to difficulties such as protein
denaturation and degradation, and problems with protein absorption. Peptides are part
of the ECM proteins which have similar stimuli of proteins while they are more stable
and easier to conjugate on material surfaces (Ventre, Causa, and Netti 2012).

4

Some of the most recent usage of peptides in breast cancer research has been reviewed
in the following 5 parageraphs.
Patched receptor binding peptides have shown to have a growth inhibitory effect in
tumors with activated hedgehog signaling (Smith et al. 2014). Remarkable growth
inhibition has been observed in breast cancer cell lines treated with patch-blocking
peptides (Smith et al. 2014).
Cancer research has been illustrated that connexin 43 is effective in proliferation,
differentiation, and migration of breast cancer cell. There are drugs available related to
this but there is a lack of knowledge in specificity of these agents. In a study, α-connexin
carboxyl-terminal (ACT1) peptide, which modulates connexin 43 has been tested in
breast cancer. The peptide is able to regulate the connexin 43 activity in breast cancer
to sustain connexin 43 -mediated gap junctional activity which cause the decrease of
malignant progression. ACT1 peptide also is able to enhance the activity of lapatinib and
tamoxifen (Grek et al. 2015).
L-peptide has showed to bind to a wide variety of cancers including breast cancers.
Treatment of mice with breast cancer patient derived xenografts (PDX) with L-peptideconjugated lipodox (LD-L) has been illustrated to result in greater suppression of tumor
growth than lipodox (LD) alone (Lee et al. 2015).
Cell surface nucleolin is known to be overexpressed in cancer cells and also it is a marker
for tumor angiogenic (Fonseca et al. 2015). To investigate whether nucleolin was a
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common receptor among breast CSC and non-stem cancer cell (non-SCC), a group of
researchers functionalized liposomes with the nucleolin-binding F3 peptide which
targeted both nucleolin-overexpressing putative breast CSC and non-SCC. An in vivo
assay showed that surface nucleolin overexpression could be related to the triple
negative breast cancer cells which potentially connect the nucleolin expression to the
stem-like properties in triple negative breast cancer cells (Fonseca et al. 2015) .
Proliferating cell nuclear antigen (PCNA) is one of the important regulators in the DNA
replication and repair process. A peptide (caPeptide) as a mimic of PCNA has been
synthesized and delivered into cells using a nine-arginine linking mechanism. R9-cccaPeptide displayed cytotoxicity in MDA-MB-436, a triple-negative breast cancer cell
line. R9-cc-caPeptide has also been resulted in blocking the association of PCNA with
chromatin (Smith et al. 2015).

1.3.1. Importance of Fibronectin and its Peptides
Fibronectin (FN) is one of the important ECM glycoprotein that exists in fibrillar form in
all tissues during life. Its formation is a cell-mediated process and is essential for life. FN
fibrils form linear and branched meshworks in order to connect neighboring cells to
each other. FN is a multidomain molecule that has different domains for interacting with
other ECM proteins including other FN proteins, cell receptors, and glycosaminoglycans
(GAGs). This arrangement of domains allows FN to bind to cells and molecules at the
same time. FN has binding sites for collagen/gelatin, heparin, fibrinogen, heparin sulfate
glycosaminoglycans, integrins, and other molecules (Singh, Carraher, and Schwarzbauer
6

2010). It plays a major role in cell adhesion, growth, migration, and differentiation
(Pankov and Yamada 2002). Altered fibronectin expression, degradation, and
organization have been associated with a number of diseases, including breasr cancer
and fibrosis (Williams et al. 2008). Observing tumors and tumor-derived cell lines have
been

attributed

to

the

decreased

fibronectin expression,

increased

fibronectin degradation, and/or decreased expression of fibronectin-binding receptors
such as α5ß1 integrins (Hynes 1990). So far, the effects of several peptides derived from
different domains of fibronectin such as WQPPRARI (Hettick, Ruwona, and Siegel 2009,
Van Den Heuvel, Jefferson, and Jacobs 2005, Yun, Kim, and Jang 2013, Woods et al.
1993, Hoesli et al. 2014, Mooradian et al. 1993, Ouchani et al. 2012, Wilke and Furcht
1990, Sagnella et al. 2005, Björklund and Koivunen 2005, Garagorri et al. 2008),
SPPRRARV (Mooradian et al. 1993, Sagnella et al. 2005), LIGRKK (Hettick, Ruwona, and
Siegel 2009, Tong 2000), RGD (Wierzba et al. 1995, Fischbach et al. 2009, Naghdi et al.
2014, Panda et al. 2010), and RYD (Murray et al. 2002, Knight 2001, Guo et al. 2005) on
different cell lines behavior such as cell adhesion, proliferation and migration have been
studied. In the following seven paragraphs a brief summary of these studies has been
provided.

1.3.1.1. WQPPRARI Peptide
WQPPRARI is one of the well-known heparin binding peptides which is derived from the
COOH terminal heparin binding domain of fibronectin. This peptide is famous for its cell
adhesion features (Hettick, Ruwona, and Siegel 2009, Van Den Heuvel, Jefferson, and
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Jacobs 2005, Yun, Kim, and Jang 2013, Woods et al. 1993). It has been shown that
WQPPRARI is able to improve umbilical vein endothelial cell adhesion, expansion, and
motility through focal adhesion formation and FAK activation (Hoesli et al. 2014);
enhance cell adhesion, spreading, and migration of rabbit corneal epithelial cells directly
(Mooradian et al. 1993); promote cell adhesion, spreading, and migration of normal and
leukemic progenitors through direct interaction with α4ß1 (Ouchani et al. 2012);
increase cell adhesion and spreading of human keratinocytes and saphenous vein
endothelial cells (Wilke and Furcht 1990); and improve human pulmonary artery
endothelial cell adhesion and spreading through local adhesion (Sagnella et al. 2005).
The WQPPRARI peptide is able to stimulate expression of MMP-1 and MMP-9 in
fibroblast plates on a fibronectin fragment, lacking the heparin binding domain. This
stimulation is mediated by α5β1 and α4β1 integrins (Björklund and Koivunen 2005). It
should be pointed out that, there is also a study on Keratocyte behavior in threedimensional photopolymerizable poly (ethylene glycol) hydrogels which used the
sequence WQPPRARI, tethered to hydrogels, and showed that it enhances adhesion,
spreading, and migration of corneal epithelial cells to the hydrogels (Garagorri et al.
2008).

1.3.1.2. SPPRRARV Peptide
The other COOH-terminal heparin-binding domain of fibronectin is SPPRRARVT. This
peptide can support cell attachment of fibroblasts (Sagnella et al. 2005); RCE cell
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adhesion and spreading (but not RCE cell migration) (Mooradian et al. 1993); and also
human pulmonary artery endothelial cell adhesion and growth (Sagnella et al. 2005).

1.3.1.3. LIGRKK Peptide
KNNQKSEPLIGRKKT is another heparin-binding peptide that derived from the COOHterminal heparin binding domain of fibronectin which mediates cell adhesion for a
variety of cell types and promotes neurite outgrowth. The basic structural features
necessary for the activity have been identified in the COOH-terminal residues, LIGRKK
(Hettick, Ruwona, and Siegel 2009). This biologically ”active” sequence has been found
in several other heparin/heparan sulfate-binding peptides such as LIGRKK derived from
laminin, which helps fluoropolymer surfaces for the enhancement of nerve cells
interactions (Tong 2000).

1.3.1.4. RGD Peptide
RGD, another well-known peptide, is a sequence in extracellular matrix proteins such as
fibronectin, collagen, and laminin that mediates cell attachment by interacting with
proteins of the integrin family of cell surface receptors (Wierzba et al. 1995). It has been
shown that human breast cancer cells, MDA-MB-123, cultured in a hydrogel based
culture system coupled to RGD are able to secrete more interleukin 8 (IL-8) compare to
the cells cultured in a hydrogel based culture system without any conjugated peptide.
Up regulation of IL-8 is critical in control of tumor vascularization. Therefore, 3D RGD
coupled culture systems could regulate cancer cell angiogenic signaling, and controlled
local and systemic blockade of IL-8 signaling (Fischbach et al. 2009).
9

Polyethylene glycol hydrogel (PEG) has been studied as a 3D culture system for neuron
cells as well. It has been reported that neurite outgrowth was improved in systems with
conjugating RGD to PEG polymer. Therefore, NSC survival, proliferation and
differentiation are enhanced when the cells are cultured in 3D-PEG–RGD compared to
3D-PEG environments (Naghdi et al. 2014).
Moreover, proliferation and growth of mammalian cells (HeLa and L929) in a 3D
environment with a dipeptide hydrogel chemically functionalized with a pentapeptide
containing Arg-Gly-Asp (RGD) motif has been investigated. The functionalized gel
exhibited enhanced cell growth promoting properties, and promoted 3D growth and
proliferation of cells for almost 2 weeks (Panda et al. 2010).
RGD peptide also has been used to examine the effect of substrate stiffness on melanoma cell
treatment responsiveness. Human cell lines derived from radial growth phase (WM35) and
metastatic melanoma (A375), PEG hydrogels as a cell culture system and PLX4032 as
pharmacological inhibitor were used. In this study, it was found that in A375 cells, matrix
elasticity did not alter cell morphology or apoptosis with PLX4032 treatment. But in WM35 cells,
matrix elasticity increased apoptosis and smaller focal adhesions on compliant substrates
(Tokuda, Leight, and Anseth 2014).

In a study, polyethylene glycol (PEG) hydrogels, attached to RGD was used and its ability
to support the growth of androgen-dependent LNCaP prostate cancer cells was
investigated. It was found that, the mechanical properties regulate the growth of LNCaP
cells in the PEG hydrogel. They showed that after 28 days of culture, LNCaP cells
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formed tumor-like structures in 3D culture, with hypoxic and apoptotic cores (Sieh et al.
2012).
In another study, by using PEG, modified with RGD and another laminin derived peptide,
murine models of lung adenocarcinoma investigated. The focus was on how matrix can
influence epithelial morphogenesis of a metastatic cell line (344SQ). 344SQ
encapsulated in bioactive peptide-modified, matrix metalloproteinase–degradable PEG
hydrogels formed lumenized epithelial spheres. Changing matrix stiffness and peptide
concentrations affected epithelial morphogenesis, apoptosis , proliferation, and
expression of epithelial polarity markers (Gill et al. 2012).
Streptavidin is a biotin-binding tetrameric analogue of avidin, produced by the soil
bacterium Streptomyces avidinii. Streptavidin, like fibronectin, contains an RGD-like
sequence RYD, which promotes adhesion to the integrin receptor α5β1. This sequence,
Arg- Tyr-Asp-Ser (RYDS), exhibits structural homology to Arg-Gly-Asp-Ser (RGDS).
Binding of streptavidin to cell surfaces mediated through this RYDS domain, can be
inhibited by using fibronectin as well as RGD- and RYD-containing peptides (Murray et
al. 2002). Synthetic peptides containing such a sequence are able to mimic the integrinmediated binding of the entire protein(s).

1.3.1.5. RYD Peptide
It was proposed that RYD in ARRSPSYYRYDGAGPYYAMDY functions as an analogue to
RGD in fibrinogen. This peptide comprised the binding domain for the αIIbβ3 receptor. A
linear peptide which is consistent with the sequence above was synthesized and was
11

found to be an inhibitor of both fibrinogen and PAC-1 binding to activated platelets.
Exchanging RGD for RYD in the aforementioned peptide, increased its activity 10-fold
(Knight 2001). Also the sequence RYD has been introduced into the dendroaspin scaffold
in order to replace RGD. The RYD sequence produced a similar IC50 value to the RGD
sequence, in inhibiting A375-SM cell (β-3 integrin) adhesion to collagen (Guo et al.
2005).

1.3.2. Importance of Laminin and its Peptides
Basal lamina is mostly made of Laminin. This protein plays a critical role in cell
differentiation, migration, and adhesion, as well as cell phenotype and survival. Laminin
is linked to type IV collagen via entactin (Smith and Ockleford 1994), fibronectin
(Ockleford et al. 1993),and perlecan [28]. Moreover, this glycoprotein, Laminin, binds to
cell membranes through integrin receptors and other plasma membrane molecules,
such as the dystroglycan glycoprotein complex (Haralson, Hassell, and Streuli 1995).
Through these interactions, laminin causes cell attachment, differentiation, shape, and
movement (Haralson, Hassell, and Streuli 1995, Colognato and Yurchenco 2000).
As it has been shown in [30], laminin plays a critical role in regulating cancer cell
migration and facilitating tumor cell invasion. Laminin establishes one of the essential
components of basement membranes (BMs) as it is involved in cellular adhesion to BMs
and ECM. Invading tumor cells are capable of attaching to the matrix through specific
laminin receptors which is present on their cell membranes. Afterward, these invading
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tumor cells release protease in the interstitial, consequently, promote BM disruption
and cell diffusion (Albrechtsen et al. 1981).

1.3.2.1. IKLLI Peptide
IKLLI is a sequence shown to be active in laminin (Fischbach et al. 2009). Several
peptides containing the IKLLI sequence in the α 1 chain of laminin-1 such as
CSRNLSEIKLLISRARK, EIKLLIS, and SEIKLLIS were found to mediate heparin binding and
cell adhesion of PC12 cells as well as promoting neurite outgrowth in these cells.
Furthermore, the CSRNLSEIKLLISRARK and SEIKLLIS sequences also mediated
proliferation in PC12 cells. As noted above, an IKLLI-containing peptide derived from the
laminin α 1 chain may be an active site of laminin and its cell adhesion maintenance may
be due to interaction with both integrin a3b1 and cell surface heparan sulphate
proteoglycan (TASHIRO et al. 1999).
These Neurons expressed integrin b1, beside the fact that the treatment of cultures
with an antibody against integrin b1 eliminated the protective effect of laminin.
Moreover, neurons maintained on laminin displayed a continued activation of the Akt
signaling pathway. The IKLLI-containing integrin-binding peptide is capabale of
mimicking the neuroprotective effect of integrin engagement by laminin. Due to this
fact, it can be well-understood that the IKLLI is an active sequence of laminin.
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1.3.3. Importance of Elastin and its Peptides
Degradation is a requirement for cancer progression. This is due to the fact that, ECM
degradation is vital to allow cell migration through its three-dimensional architecture
and also to generate ECM fragments. ECM proteolysis causes the release of matrix
fragments that exhibit proper biological activities. This degradation of ECM is coincident
with the degradation of Elastin, a major component of ECM that confers elasticity to
tissues (Panda et al. 2010). Protease-driven elastin degradation happens during
physiopathological processes such as cancer progression, which generates bioactive
elastin-derived peptides that are thought to contribute to tumor progression (Devy et al.
2010). In another words, Elastin peptides control proliferation, chemotaxis, and
protease expression.

1.3.3.1. VAPG Peptide
VGVAPG is an elastin-derived peptide shown to block ceramide-induced apoptosis in
human skin fibroblast cells. The elastin peptide treatment leads to activation of the proapoptotic protein Bad, and caspase-9 (Cantarelli et al. 2009). As mentioned in [36],
elastin-derived peptides raise invasive capacities of lung cancer cells by posttranscriptional regulation of MMP-2 and uPA.
The VAPG peptide sequence is repeated several times in human elastin and most likely it
is one of the breakdown products after the degradation of elastin. The VAPG elastin
peptides could bind to three identical receptors, namely; (i) galectin-3, (ii) integrin αvβ3,
and (iii) elastin-binding protein. It is also have been investigated that, VAPG is able to
14

increase the invasive potential of melanoma cells mostly by galectin-3 (Pocza, Falus, and
Darvas 2009).
In a study, VAPG peptide sequence attached to a hydrogel material, and its effects on
smooth muscle cell adhesion and spreading have been studied. The VAPG sequences
was specific for adhesion of smooth muscle cells while fibroblasts, endothelial cells, and
platelets cannot adhere to VAPG (Gobin and West 2003).
The effects of cell adhesion due to the VAPG peptide on vascular smooth muscle cells
were also examined in (Gill et al. 2012). These cells more strongly adhered to the
surfaces modified with adhesive ligands. In addition, cell migration was higher on
surfaces with the adhesive ligand than on control surfaces. Moreover, cell proliferation
was lower on adhesive surfaces. Likewise, in hydrogel which is functionalized with
VAPG, cell proliferation was lower in comparison with control groups (Gill et al. 2012).
Matrix protein synthesis by cells cultured on materials that was modified by cell
adhesion ligands, like the VAPG peptide, were examined in (Smith and Ockleford 1994).
While initial adhesion of smooth muscle cells, endothelial cells, and fibroblasts increased
on the higher density of peptides on surfaces, all cell types had less production of matrix
on the more highly adhesive surfaces. This result may actually pose limitations for the
use of bioactive materials, such as in tissue engineered scaffolds since matrix production
is an important aspect of tissue formation (Mann et al. 1999).
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In this Study, the role of these integrins binding peptides (RYD, RGD, IKLLI, and VAPG)
and heparin binding peptides (WQPPRARI, SPPRRARV, LIGRKK, and IKLLI) on the
maintenance and behavior of breast CSCs encapsulated in PEGDA has been investigated.

1.4. CSC microenvironment and pH
Tumor microenvironment is extremely acidic (pH ~6.8) compared to normal tissue (pH
~7.4) which affect tumorigenesis, angiogenesis and metastasis activity of cancer cells
exclusively (Song, Griffin, and Park 2006). It has been shown that tumor
microenvironment has lower pH and is more acidic in comparison with normal tissue,
and this is due to anaerobic and aerobic pathways. In a tumor, vascularization is not
homogeneous and adequate to feed enough nutrition, specifically oxygen to rapid
dividing cancer cells. Lack of oxygen is the main reason for acid production. In hypoxia,
cells undergo glucose uptake and glucose goes through glycolytic pathway instead of
respiratory pathway which causes the production of lactic acid and reduction of pH in
the microenvironment (Song, Griffin, and Park 2006, Tannock and Rotin 1989).
Moreover, under hypoxia condition, ATP hydrolysis also causes the acidification of
tumor microenvironment. On the other hand, it has been shown that in cancer cells,
glucose undergo glycolysis even in the presence of sufficient oxygen in order to produce
lactate.
Cancer cells require high amount of lactate because it helps them to escape from
immune cells. In the presence of lactate produced from tumor cells, T cells do not
secrete lactate and this interferes with T cells function. Lactate can inhibit the function
16

of dendritic cell activated by antigen-specific autologous T-cell stimulation. Moreover, it
also inhibits monocyte migration and cytokine release (Kato et al. 2013).
Moreover, tumor cells undergo glycolysis even in sufficient oxygen condition because of
their advantage. The glycolysis pathway produces acid and the acidic extracellular
environment help cells to become invasive and proliferative (Gatenby and Gawlinski
2003).
On the other hand, it has been shown that the pentose phosphate pathway is highly
active in tumor cells. CO2 is one of the products of this pathway while there is a large
amount of carbonic anhydrase (CA) is also present in a tumor. CO2 can be processed to
H+ and HCO3- by CA as a catalyzer (Gatenby et al. 2006). Therefore, CO2 is another
important reason for acidic PH of tumor microenvironment (Helmlinger et al. 2002).
It has been shown that Acidic pH can induce EMT in some types of cancer cells such as
lung and melanoma cancer cell lines (Peppicelli et al. 2014, Suzuki et al. 2014).
Moreover, acidic pH has also been associated to the expression of some genes that are
contributed to metastasis of cancer cells such as metastasis of melanoma cells to the
lungs (Rofstad et al. 2006). Acidic pH increases the expression of some genes that are
involved with pro-metastatic factors. It has been shown that when melanoma cells
incubated in acidic culture medium, had a higher metastatic rate accompanied by
proteinase MMP-9 and NHE activation (Gatenby et al. 2006, Kato et al. 2013) and a
higher angiogenesis by acid induced production of VEGF-A and IL-8 (Gatenby et al.
2006).
17

The glycolytic activity in tumor cells enhances tumor invasion. Protons (H+) produced by
cancer cells diffuse (carried by a buffering agent) from tumor to the normal tissue
nearby by using transporter proteins such as Na+/H+ exchanger (NHE) ,and cause the
decrease of pH in normal tissue. It has been shown that the Na+/H+ exchanger type 1
(NHE1) was an important regulator of H+ efflux in breast cancer cells MDA-MB-231
(Stock et al. 2005).
Therefore the intracellular pH of cancer cells does not become acidic while it is slightly
alkaline and in fact this alkaline pH is suitable for cell proliferation. The acidic pH causes
normal cells to undergo cell p53-dependent apoptosis but some of the tumor cells
survive which are resistant to acidic pH, which is probably due to mutation in p53 or
other components of apoptosis pathway. Low pH causes the extracellular matrix to
degrade by proteolytic enzymes that highly active in low pH and produces by fibroblasts
and macrophages (Gatenby and Gawlinski 2003). Moreover, it enhances angiogenesis by
using acid induced vascular endothelial growth factor and interleukin 8, and inhibits
immune system to response to tumor antigen (Kato et al. 2013). Therefore tumor cells
become more invasive as they disrupt the environment, and provide a better condition
for them to proliferate. Cell-cell junctions of tumor cells become separated when cells
move in to their surrounding tissue. Acidic pH helps tumor cells to destruct the
adherence junction. This is by Src activation, that causes E-cadherin degradation
through a the protein kinase activity (Gatenby et al. 2006).
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To wrap up, pH is one of the important factor in tumor microenvironment and although
the effect of pH has been studied on some cancer cell lines (Peppicelli et al. 2014, Suzuki
et al. 2014, Rofstad et al. 2006) , the effect of pH on breast cancer stem cells has net
been investigated yet.
Herein, we used PEGDA having modulus of 5 kpa to study the role of acidic pH (6.8) in
the maintenance of breast CSCs. Having a good understanding of the role of this factor
on regulation of CSCs can offer important information on the behavior of breast CSCs in
their tumor microenvironment.

1.5. CSC Microenvironment and Shape
Tumor transformation and metastasis is involved with changes in mechanical properties
of cells and cell’s microenvironment including mechanics, shape, and topology of ECM.
Cells are able to sense the rigidity (elastic resistance) of ECM and balance this force by
exerting contractile stresses. The balance force is very important in regulating the
structure, motility, proliferation, and differentiation of tumor cells. Cells exert this force
by the use of adhesion receptors (e.g., integrins), intracellular focal adhesions,
cytoskeletal networks, and molecular motors. Therefore, direct connection between the
extracellular matrix (ECM) and the intracellular environment can control fundamental
behaviors such as differentiation, morphology, motility changes, and alterations in cell
cycle which can contribute to tumor transformation, invasion, and metastasis (Kumar
and Weaver 2009, Tse, Weaver, and Di Carlo 2012, Kilian et al. 2010). It has been shown
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that gene expression, self-renewal, and differentiation of malignant cells

can be

affected by geometrical confinement. Confinement of human cervical carcinoma cells
changed the average tumorsphere size and cluster size affected MCF10A cells
proliferation (Jabbari et al. 2015).
Previously we have encapsulated MDA-MB-231 cells in circle shape 50, 75, and 250 µm
patterned PEGDA gels and incubated for 9 days in CSC medium. It was shown that as the
patterns became smaller the expression of breast CSCs became higher. Therefore, using
micropatterning and the confinement of breast CSCs can help to get a higher expression
of CSCs markers (Jabbari et al. 2015) which can be used in further studies on breast
CSCs. So far, breast cancer stem cells encapsulated in PEGDA or in micropatterned
PEGDA form tumors in spherical shape. Herein, we hypothesize that if the shape of
micropatterned changed, the shape of tumors may change as well. Therefore, we
designed photomask with circle, square and rectangle micropatterns in order to shape
the PEGDA and investigate the effect of them on maintenance of breast cancer stem
cells in PEGDA.

1.6. Why Choosing
Microenvironment?

PEGDA

for

Investigation

on

CSCs

and

Their

CSCs are a small population of tumor cells that are drug resistant, capable of
differentiation, metastasis, and self-renewal through specific pathways provided in the
CSCs niche. On the other hand, cancer development is a hard process to follow as it may
take many years in vivo. Thus, it is required to design in vitro systems in order to
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investigate cancer tumor formation and progression on the molecular level. This
molecular level investigation has been performed in two or three dimensional cell
culture systems.

1.6.1. 2D Cell Culture Systems
Classical-two dimensional cell culture systems have provided the majority of modern
cancer biology science. For instance, the most common substrates for supporting cell
growth have been made from polystyrene or glass and have been made in shape of a
flat two-dimensional (2-D) surface. However, the main problem for this 2-D system is
the assumption that body physiology can be correctly reproduced using a cellular
monolayer. Obviously, a eukaryotic cell cannot develop same properties on a twodimensional glass or polystyrene substrate compared to the 3D extracellular matrix
found in innate tissue. When cells are cultured in 2-D plates, they are attached to rigid
and flat substrates which cause cells to be polarized and get sheet-like morphology
(Alemany-Ribes and Semino 2014, Haycock 2011). These cells are exposed to excessive
nutrition and oxygen. Moreover, in 2-D cultures cells have different surface receptors'
orientation and clustering; therefore,

they have different ECM secretion in

composition, configuration and amount and as a consequence, they don’t have normal
signaling that comes from natural ECM (Alemany-Ribes and Semino 2014). Also, their
cell growth rate, migration and apoptosis change in this classical culture systems (Chen
et al. 2012). For the purpose of CSCs culturing, suspension (non-adherent plates) are
commonly used which again have similar problems as adherent substrates.
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Based on the above discussion, it can be concluded that, the culture of cells in 2-D
systems is certainly too simple and neglects many important parameters for
reproducing the cell and tissue environment, such as of mechanical cues, cell-matrix and
cell-cell communication (Haycock 2011).
To be more specific in cancer, metastatic cells are not adherent and cannot form tight
focal adhesions. Thus, 2-D cultures are not applicable for them. Furthermore, in multiple
passages of cancer cells, those that have rapidly proliferation are the target of natural
selection, whereas these rapidly proliferative cells are sensitive to therapies that target
rapidly dividing cells while this is not the same condition for all cells in a tumor
(Alemany-Ribes and Semino 2014).
Some parameters such as gradient of nutrients and growth factors as well as cell-cell
and cell-matrix communication which are known to play crucial roles in cancer initiation,
progression, and metastasis cannot be mimicked accurately in 2-D culture systems. As
an example, cancer cells which are cultured in 2-D plates are less malignant in
comparison with those under in vivo conditions (Kitai et al. 2005). Therefore, results
from drugs that are designed to target cell-cell interaction, epithelial to mesenchymal
transition (EMT), and CSC are not trustable(Chen et al. 2012).

1.6.2. Animal Models in Cancer Research
Animal models act as another alternative that are commonly used for the study
purposes of molecular pathways and drug reaction in cancer research. In these cases,
either animal tumors grown in syngeneic animals or human tumors grown in
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immunocompromised animals are used for the research purposes. However, animal
models may not satisfactorily reproduce the structures of human cancers in vivo (Yang
et al. 2013).
Animal models constitute a wide range of models for cancer study:
1- Ectopic xenografts of tumor-derived cell lines or tissue, embedded into
syngeneic or immunecompromised.
2- Orthotopic xenografts of tumor cell lines or tumor tissues are implanted within
the proper organ or tissue.
3- Germ-line transgenic and conditional transgenic models (GEMMs)
4- Primary human tumorgrafts
5- Carcinogen-promoterinduced multi-stage tumor models
A review of pros and cons of these methods are available (Ruggeri, Camp, and
Miknyoczki 2014).However, they are not explained here in details as describing them is
out of scope of this thesis. As some important and most common

examples of

disadvantages related to these methods are lack of native tumor microenvironment,
limited engraftment rates, labor intense, time consuming, and ethically problematic
(Ruggeri, Camp, and Miknyoczki 2014, Sachs and Clevers 2014).

1.6.3. 3D Cell Culture Systems
To have a suitable cell culture system, it should provide a 3D matrix having tunable
mechanical properties with a capacity of co-culturing cells in order to provide cell-cell
interactions and the exchange of growth factors and other biological effectors.
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Available 3D in vitro co-culture models satisfy these requirements (Kim 2005) which are
also necessary in CSC research.
In many 3-D models, cell lines or cells from dissociated tissues are implanted and
cultured in 3-D matrices in order to promote cell–cell interaction, adhesion, migration,
and in vivo–like morphogenesis. There has been a big difference in all aspects of cell
behavior; (i) cell shape, (ii) cell growth, (iii) gene expression, and (iv) the response to
stimuli between 2-D and 3-D culture systems. Based on these differences, increasing the
attraction of researches toward utilizing 3-D environments for the most recent
biomaterial directed stem cell manipulation researches can be better understand (Yang
et al. 2013).
In order to work in 3-D environments, in vitro or in vivo, biomaterial-based matrices
have been used as an important tool. These 3-D environments provide ideal matrices for
cell-cell and cell-matrix interaction. Moreover, their properties can be adjusted for
specific features such as desired fluid transport, delivery of bioactive molecules, and
induction of signal transduction. These properties are important since they direct cell
adherence, nutrient/waste transport, cell proliferation, cell differentiation, and in
cancer stem cells studies, tumor sphere formation. Most of these materials can be
modified in order to adjust all of the mentioned critical matrices characteristics.
There are a variety of synthetic and natural materials that have been used for studying
SC and CSCs behavior by manipulating biomaterial-based matrices properties. One of
the most commonly type of these materials is Hydrogels. Hydrogels are a 3-D polymeric
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network that can swell under biological conditions. With the ability of swelling,
hydrogels have high water content, therefore they can offer environments that are
closer to natural soft tissue in comparison with other polymeric materials. Additionally
they are more biocompatible as they are highly permeable for oxygen, nutrients, and
other water soluble metabolites. Therefore, hydrogels are ideal for cell encapsulation
(Albrechtsen et al. 1981, TASHIRO et al. 1999, Devy et al. 2010, Cantarelli et al. 2009,
Pocza, Falus, and Darvas 2009, Gobin and West 2003, Mann et al. 1999).

Most

hydrogels can be made by photopolymerization under mild conditions with consistent
seeding of cells throughout the scaffold (Ifkovits and Burdick 2007, Chung and Park
2009, Slaughter et al. 2009).
Hydrogels are divided in to three main groups; (i) natural, (ii) synthetic and (iii)
synthetic/natural hybrid hydrogels. There are many types of natural polymers such as;
• Proteins: gelatin, collagen, Matrigel™, fibrin, silk, and lysozyme (Glowacki and Mizuno
2008, Sakai et al. 2009, Wang et al. 2006, Mol et al. 2005, Yan et al. 2008, Kleinman and
Martin 2005).
• Polysaccharides: hyaluronic acid (HA), agarose, dextran, and Chitosan (Leach et al.
2003, Denizli et al. 2004, Kuo and Ma 2001, Kim et al. 2008).
However, using natural biomaterials has some disadvantages. These disadvantages
include limitation in the adjustment of physical and chemical properties, difficulty in
modifying degradation rates, and the difficulty in sterilization and purification as well as
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pathogen/viral issues when isolating from different sources. Furthermore, there are
problems with isolating and studying cell response to the individual factors in the
microenvironment. This problem is associated with the fact that naturally derived
matrices have many interactions with cell surface receptors which interfere with cell
responses to specific factors (Yang et al. 2013).
In order to overcome the disadvantages of natural hydrogels, synthetic hydrogels have
been considered as a desirable alternative. Synthetic polymers have more reproducible
physical and chemical characteristics, which is important for the production of tissue
engineered scaffolds. One of these synthetic polymers is Poly ethylene glycol.

1.6.4. Using PEGDA with 5kpa Modulus for this Research
Poly ethylene glycol (PEG) polymer is investigated extensively because of its
specifications, including solubility in water and organic solvents, low protein adhesion,
nontoxicity, and nonimmunogenicity (Buxton et al. 2007, Beamish et al. 2010).
Additionally, the end hydroxyl groups of PEG molecules can be grafted with various
functional groups such as acrylate in order to create hydrogels (Zhu 2010).
Among the parameters in the microenvironment, stiffness (elastic modulus) plays a
crucial role in regulating cell function in 2-D and 3-D culture systems (Rehfeldt et al.
2007). As it has been shown in (Sachs and Clevers 2014, Ifkovits and Burdick 2007,
Chung and Park 2009), in 3-D culture systems, encapsulated stem cell differentiation,
and the balance of cell proliferation, and apoptosis can be directed by the stiffness of
the hydrogel. Cells need to respond properly to the environmental signals for survival.
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As mechanical properties and composition of hard and soft tissues are different, cells
can sense and respond to the matrix stiffness in their natural environment by making
the proper ECM composition. Similarly, the proliferation, differentiation, migration, and
apoptosis of cancerous cells in the tumor tissue are regulated by matrix stiffness
(Discher, Janmey, and Wang 2005, Schrader et al. 2011, Verbridge, Chandler, and
Fischbach 2010).
In this thesis, the inert poly ethylene glycol diacylate hydrogel (PEGDA), in a certain
moduli based on previous studies, as a 3-D cell culture system has been used in order to
investigate the role of cell binding peptides, microenvironment pH, and matrix shape on
the maintenance of breast CSCs. It has been shown that only breast CSCs among breast
cancer cells can form tumor sphere in PEGDA (Jabbari et al. 2015). Having a good
understanding of the role of these environmental factors on regulation of CSCs can
provide significant information on the behavior of breast CSCs in their tumor
microenvironment.
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Chapter 2
Results and Discussion
2.1. Results and Discussion for Peptide Experiment
We have shown that cancer cells can form tumorspheres in the PEGDA gel with respect
to the gel modulus (Yang et al. 2013). MDA-MB-231 human breast carcinoma cells
formed cancer tumorspheres in the gel with an optimum modulus of 5 kPa, and the
sphere formation was correlated with the expression of CSC markers (Yang et al. 2013).
In order to determine if synthetic cell binding peptides derived from ECMs’ components,
attached to PEGDA gel, could affect the sphere formation of MDA-MB-231 cells in the
PEGDA gel, different peptides such as; (i) VAPG, (ii) IKLLI, (iii) WQPPRARI, (iv) SPPRRARV,
(v) LIGRKK, (vi) RYD, and (vii) RGD have been conjugated to the gel with a 5 kPa modulus
in concentrations of 1%, 2%, 4%, 6%, and 9% (mg/mg). Sphere formation in samples was
compared with the sphere formation of MDA-MB-231 cells encapsulated in PEGDA
polymer with a 5 kPa modulus and no peptide. To achieve this goal, different
measurements such as; fluorescent images, cell number, sphere number, sphere size,
and

expression

of

CSC

markers
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have

been

performed.

2.1.1. Comparison of Sphere Formation of Tumor Cells Encapsulated in PEGDA
with Different Conjugated Peptides in Fluorescent Images
Figure 2.1 illustrates the effects of different peptides on the sphere formation of cells,
encapsulated in PEGDA gel in fluorescent images. As the concentration of peptides
increase, the ability of the cancer stem cells to form spheres decreases. That means,
there are a larger number of tumor spheres in groups with no peptide compared to the
1%, 2%, 4% concentrations. There was no sphere formation for all peptides in 6% and
9%.
As can be seen in all of the subfigures of Figure 2.1, larger spheres exist in the control
group. By the increase of the peptides concentratons to 1% and 2% the tumors sphere
size decreases gradually. In Figure 2.1, there are only four different concentrations (0%,
1%, 2%, and 4%) that have been shown. Concentrations of 6% and 9% are not shown
here as there was no tumorsphere formation in these concentrations for any of the
peptides.

2.1.2. Comparison of Cell Density, Sphere Size, and Sphere Density of
Tumorspheres for Different Peptides
The cell density for the cells encapsulated in PEGDA gel and incubated for 9 days in stem
cell culture medium are shown in Figures 2.2 (a). The cell density of MDA-MB-231 cells
encapsulated in PEGDA in the presence of all of the peptides decreased gradually as the
0%

1%

2%

4%

concentration of peptides increased, suggesting that peptides crosslinked to the PEGDA
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Figure 2.1 Comparison of tumorsphere formation in PEGDA gels conjugated with
peptides. Illustrate of fluorescent images of the tumorsphere size and distribution for
MDA_MB_123 tumor cells encapsulated in PEGDA gels with different concentrations of
VAPG, IKLLI, WQPPRARI, SPPRRARV, LIGRKK, RYD, and
RGD peptides.
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are able to decrease the proliferation of tumor cells and the rate of this decrement
increased with respect to the concentration increment.
The cell density was normalized with respect to the control groups without any peptides
for all of the peptides. The cell density decreased significantly for all peptides with a
concentration of 2% or more (mg/mg). Figure 2.3 (a) Displays the comparison of cell
density for the peptides used in a 0.02 concentration. The cell density of the samples
with a 2% peptide concentration decreased to 0.738469±0.059071, 0.372907±0.068205,
0.16477±0.071641,

0.52825±0.044298,

0.150917±0.065204,

0.362006962±0.044315007, and 0.296782544±0.117010065 per cell density of the
control groups, for VAPG, IKLLI, WQPPRARI, SPPRRARV, LIGRKK, RYD, and RGD,
respectively. Cell density decreased significantly for all of the peptides in this
concentration with respect to the control group. Moreover, there was a significant
difference in cell density between peptides and their scrambled ones, whereas cell
density did not change considerably with respect to the control group for scrambled
peptides, meaning that the effect of reducing cell number is specific for the peptides. In
comparison with 2%, a 1% peptide concentration showed less success for reducing the
cell number density with respect to the control groups, shown in figure 2.3. (b). There
was no significant difference between cell number of cells encapsulated with peptides in
a 1% concentration compared to the control group with no peptide except for RYD.
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Figure 2. 2 Comparison of cell density, tumoresphere density and and sphere size of
the cells in PEGDA gels conjugated with peptides. Illustrate the effect of the peptides
on normalized cell density (a), tumorsphere density (b) and sphere size distribution (c)
for MDA-MB-123 tumor cells encapsulated in PEGDA gel and incubated in CSC medium
for 9 days.

32

Normalized Cell Density

1.2
1
0.8
0.6
0.4
0.2
0

0.02
Peptide
Scrambled Peptide

Peptides

(a)
Normalized Sphere
Density

1.5

Peptide 0.01
Scrambled Peptide

1

0.5
0

Peptides

SNormalized phere
Density

(b)
1.4
1.2
1
0.8
0.6
0.4
0.2
0

Peptide
0.02
Scrambled Peptides

Peptides

(c)
Figure 2.3 Comparison of cell density in 0.01 and 0.02 concentrations, and
tumoresphere density in 0.02 of the cells in PEGDA gels conjugated with peptides.
Representative the effect of the peptides in 0.02 concentration (a) and 0.01
concentration (b) on normalized cell density, and tumorsphere density in 0.02
concentration (c) for MDA-MB-123 tumor cells encapsulated in PEGDA gel and
incubated in CSC medium for 9 days.
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The variation in the cancer tumorspheres density has similar trends with respect to cell
density. As the concentration of the conjugated peptides increased, the cell density
decreased, meanwhile the cancer tumor spheres density reduced as well. In Figure 2.2
(b), the sphere density was normalized with respect to the control groups for all the
peptides. The highest densities of sphere were within samples with no peptide
concentration. In a 2% concentration, shown in figure 2.3 (c), all of the peptides reduced
the ability of cancer stem cell in order to form tumorspheres considerably with respect
to the control group. The cell number density decreased to 0.43628± 0.050591,
0.19286± 0.031074, 0.431222± 0.016621, 0.275115± 0.129692 , 0.196425± 0.046058,
per cell density of the control groups, for VAPG, IKLLI, WQPPRARI, SPPRRARV, LIGRKK,
respectively. There were no spheres for RYD and RGD in this concentration. On the
other hand, the scrambled peptides were not able to have the same effect on the
cancer cells; not only the tumorspheres densities did not have a major difference with
respect to the control, but also they had a significant variance with the density in
relative peptides samples. In addition, in a 1% concentration did not show any
significant effects on the decrease of tumor density with respect to the control groups
and scrambled peptides except RYD peptide, shown in Figure 2.3 (b). In all of the 4%
concentrations of the conjugate peptides except one, SPPRRARV, as well as higher
concentrated ones the cancer stem cells were unable to form tumorspheres. This was
also true for the scrambled peptides as there were no sphere formation in high
concentrations, proposing that the prevention of the cancer stem cells from forming
tumor spheres in 4% and above concentrations is not specific to the peptides. Also, cell
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number was significantly reduced in 4% and higher concentrations for both peptides
and scrambled ones which shows that the reduction is through nonspecific interactions.
Human breast cancer stem cells formed larger tumorspheres in groups with no peptide
after 9 days of culturing in the gel. This has been shown in Figure 2.2 (c). The average
sphere size of groups with different peptides and concentrations were normalized with
respect to the control groups. The average sphere size of the cells encapsulated in
PEGDA

with

conjugated

peptides

having

2%

concentration

decreased

to

0.633892042±0.076894548, 0.526900821±0.030774561, 0.459564566±0.076799477,
and 0.509764726±0.075889146 per average sphere size in control groups for VAPG,
IKLLI, WQPPRARI, SPPRARV, and LIGRKK, respectively. In addition, there was no sphere
formation for tumor cells encapsulated in PEGDA with conjugated RYD and RGD having a
2% concentration. The average sphere size did not change significantly for scrambled
peptides in a 2% concentration showing that peptides are able to reduce the size of
spheres. Moreover, in comparison with 2%, the average size of sphere also did not
change fundamentally for both peptides and scrambled ones in a 1 % concentration
with respect to the control group with no peptide except for RYD.

2.1.3. Comparison of CD44, ABCG2, and TGF β Expressions of Tumor Cells
Encapsulated in PEGDA with Different Conjugated Peptides
Figures 2.4. (a)- (c) shows the expressions of breast CSC markers CD44, ABCG2, and TGF
β for the encapsulated cells, normalized with respect to the control group. CD44 is a cell
surface molecule that has multiple structures and functions. This molecule is involved
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in cell proliferation, cell differentiation, cell migration, angiogenesis, presentation
of cytokines, chemokines, and growth factors to the corresponding receptors, and
reducing of proteases at the cell membrane, as well as in signaling for cell survival. All
these biological properties are critical to the physiological activities of cancer cells (Eibl
et al. 1995).
ABCCG2 (ATP-binding cassette sub-family G member 2) is a membrane-associated
protein encoded by ABCG 2 gene. ABCG2 protein is part of the superfamily of ATPbinding cassette (ABC) transporters. ABC proteins transport several molecules across
extra- and intra-cellular membranes. Therefore, ABCG2 referred to as the Breast Cancer
Resistance Protein. This protein functions as a xenobiotic transporter which probably
play a role in multi-drug resistance to chemotherapeutic agents (Allikmets et al. 1996).
TGF-β (Transforming growth factor beta ) is a secreted protein that mostly
controls cellular proliferation and differentiation (Schoenhoff et al. 2009). Normally it is
acting through its signaling pathway, stops the cell cycle at the G1 stage to prevent
proliferation, cause differentiation, or stimulate apoptosis. In many cancer cells, parts of
the TGF-β signaling pathway are mutated, therefore, TGF-β no longer controls the cell
proliferation. As a consequence, the cancer cells and surrounding stromal cells
(fibroblasts) proliferate. Both cells produce higher levels of TGF-β. This TGF-β acts on the
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Figure 2.4 Comparison of CD44, ABCG2, and TGF β expressions of the tumor cells in
PEGDA gels conjugated with peptides. Illustrate the effect of peptides on the
normalized CD44 (a), ABCG2 (b), and TGF β (c) marker fold expressions of MDA-MB-123
cells encapsulated in PEGDA gel for 9 days in CSC medium.
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Figure 2.5 Comparison of normalized CD44, ABCG2, and TGF β expressions of the
tumor cells encapsulated in PEGDA gels with 2% concentration of different conjugated
peptides. Representative of the comparison of the effect of peptides in 2%
concentration on the normalized CD44 (a), ABCG2 (b), and TGF β (c) marker fold
expressions of MDA-MB-123 cells encapsulated in PEGDA gel for 9 days in CSC medium.
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surrounding stromal cells, immune cells, endothelial and smooth-muscle cells. It causes
immunosuppression and angiogenesis, which makes the cancer more invasive. TGF-β
also changes effector T-cells, which under normal condition attack cancer with an
inflammatory (immune) reaction, into regulatory (suppressor) T-cells, which turn off the
inflammatory reaction (Epstein et al. 2000).
After 9 days of incubation, CD44, ABCG2, and TGF β expression levels in the cells
encapsulated in PEGDA with no peptide was significantly higher than the level of
expressions in the cells encapsulated in PEGDA conjugated with peptides.
Figures 2.5. (a)- (c) shows the comparison of normalized expressions of breast CSC
markers CD44, ABCG2, and TGF β for the tumor cells, encapsulated in PEGDA with a 2%
concentration of different peptides for 9 days in CSC medium. As shown in Figure 2. 5.
(a), (b), and (c) for all of the peptides with 2% concentration, there is a significant
decrease in CD44, ABCG2, and TGF β expression levels of cancer cells with respect to the
control group. On the other hand, in groups with 2% concentration of respective
scrambled peptides, there is no major difference in the levels of CD44 and ABCG2
expression of cells with respect to the control group while there is a significant variance
between CD44 and ABCG2 expression of cells encapsulated with each peptide and its
scrambles one. In a 1 % concertation, WQPPRARI and RYD were more effective on
reducing the markers expression among the peptides. In a 2% concentration WQPPRARI,
RYD and RGD were more effective on reducing the markers expression among the
peptides. In 4% and higher concentrations both peptides and scrambled ones decreased
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the markers expression significantly, suggesting that the reduction is not specific to the
peptides.

2.1.4. Comparison of the Effect of Conjugated Peptides on Sphere Formation of
Tumor Cells Encapsulated in PEGDA for 9 Days in CSC Medium
Results for the measurements of cell and sphere density together with marker
expressions illustrated that in a 0.01 concentration of conjugated peptides, RYD and
WQPPRARI were the most effective peptides in reducing tumor sphere formation. In a
0.02 concentration, WQPPRARI, RGD, and RYD were the most effective peptides in
reducing the sphere formation among peptide. Plus, 4% and higher concentrations are
too high amounts of peptides which change the PEGDA matrix and cause nonspecific
interactions with breast cancer stem cells.

2.1.5. How Cell Adhesion Peptides Affect the Sphere Formation of Tumor Cells
Encapsulated in an Inert PEGDA System?
When MDA-MB-231 cancer cells are cultured in the inert PEGDA hydrogel matrix, there
is a population of these cells that have high expression of CD44 cell surface glycoprotein.
This population of cells interacts with each other to grow and divide, and eventually
form a tumorsphere. These cells which have breast cancer stem cells properties are
non-adherent and through the cell-cell interaction instead of the cell-matrix interaction
survive in the matrix; however, conjugating cell binding peptides to the matrix will cause
a competition for the cells to interact with each other or with the matrix. By binding of
the cells to the peptide ligands, cells adhere to the matrix and do not form
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tumorspheres. There should be a preference of the cell adhesion peptides for the cells
which cause some of these cell binding peptides to be more effective in reducing the
tumorsphere formation of breast cancer stem cells. The reason probably refers to the
cell surface binding receptor and intracellular pathways which will be investigated in
future studies.

2.2. Result and Discussion for pH Experiment
In this study, we investigated the effect of acidic pH 6.8, equivalent to the pH of tumor
microenvironment (Pellegrini et al. 2014), on the maintenance of breast CSCs
encapsulated in PEGDA and incubated for 9 days in CSC medium. Fluorescent Imaging,
qRT-PCR, and DNA Content measurements have been done in order to determine the
differences between breast CSC maintenance and behavior in acidic pH 6.8 and normal
pH 7.4.

2.2.1. Comparison of Sphere Formation of MDA-MB-231 Tumor Cells
Encapsulated in PEGDA and Incubated in CSC Medium with Different pH in
Fluorescent Images

Figure 2.6. Illustrates the effects of pH of the CSC medium on the sphere formation of
cancer cells encapsulated in PEGDA gel for 9 days. In CSC medium with pH 7.4 which
was used as a control, there were not a significant difference in number of tumor
spheres and their diameters compared to that in pH 6.8. Therefore, tumor cell‘s
capability of forming spheres in pH 6.8 was the same as that in pH 7.4.
PH=6.8

PH=7.4
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100 µm

100 µm

Figure 2.6 Comparison of tumorsphere formation in PEGDA gels, encapsulated in CSC
medium with PH=7.4 and 6.8. Illustrate of fluorescent images of the tumorsphere size
and distribution for MDA_MB_123 tumor cells encapsulated in PEGDA gels and
incubated in CSC medium with pH 7.4 and pH 6.8. The scale is 100 µm.

2.2.2. Comparison of Cell Number, Sphere Size, and Sphere Number of Cancer
cells in CSC Medium with Different pH
The cell density for the MDA-MB 231 cells encapsulated in PEGDA gel and incubated for
9 days in stem cell culture medium are shown in Figures 2.7.(b). The cell density of
MDA-MB-231 cells encapsulated in PEGDA end incubated in pH 7.4, and pH 6.8 was
8.1079±0.82 and 6.4191±0.53, respectively.
MCF10a cell line is a normal breast epithelial cell line which was used as control group
for the experiment. This cell line is not cancerous and does not form tumor spheres
when encapsulated in 3D PEGDA. The cell number of MCF10a cells in PEGDA with pH 6.8
and 7.2 was 0.8511±0.2183 and 2.9803±0.6523 respectively, shown in Figure 2.2. b). this
results suggests that the decrease of cell number due to the reduction of pH is more
effective on normal cells than cancer cells.
The average sphere size of MDA-MB-231 cells encapsulated in PEGDA end incubated in
pH 7.4 was 50.9189±8.45 and was 43.3028±8.05 in pH 6.8. The average sphere number
of MDA-MB-231 cells encapsulated in PEGDA end incubated in pH 7.4 was
4854.27±1321.16 and was 4045.23±934.20 in pH 6.8. MDA-MB-231 and MCF10a cell
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lines also cultured in 2D flasks for 9 days in CSC medium with pH 6.8 and 7.4. Cell
number was reduced for both of these cell lines by the decrease of pH, while the
reduction was higher for non-cancerous MCF10a cells. The results together show that
cancer cells are more resistant to acidic pH.

2D
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6.8
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(b)
Figure 2.7 Comparison MDA-MB-231 and MCF10a cell numbers cultured in CSC with
pH 7.4 and pH 6.8. Illustrate the effect of PH on (a) cell density and (b) tumorsphere
number for MDA-MB-123 tumor cells encapsulated in PEGDA gel and incubated in CSC
medium with two different pH for 9 days.
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2.2.3. Comparison of CD44, and ABCG2 expressions of MDA-MB-231 and MCF10a Cells
Incubated in CSC Medium with pH 7.4 and pH 6.8
Figures 2.8.(a)- (d) shows the expressions of breast CSC markers CD44, and ABCG2 for
the cultured cells in CSC medium with different pH. After 9 days of incubation CD44, and
ABCG2 expression levels for the MDA-MB-231 cells encapsulated in PEGDA, in CSC
medium with pH 7.4 was not significantly higher than the level of expressions for the
cells encapsulated in PEGDA, in CSC medium with pH 6.8. However, when MDA-MB-231
cells cultured on a 2D substrate, they had a higher expression of CD44 and ABCG2 in pH
6.8 compared to that in pH 7.4. While, the expression of these markers decreased for
MCF10a cells in both 2D and 3D cultures when pH was 6.8.
2.2.4. How Did Acidic PH Affect the Maintenance of CSCs?
Fluorescent imaging showed that, MDA-MB-231 cells formed tumor spheres with almost
same sizes in pH 7.4 and pH 6.8. Also, the density of tumor spheres which was counted
in fluorescent images, was not significantly different form that in normal pH.
Consistently, the cell density, measured by DNA Content measurement, as well as breast
CSC markers; including CD44, and ABCG2, measured by the use of qRT-PCR, were also
the same in acidic pH and normal PH. The populations of these cells that are
encapsulated in PEGDA and formed tumorspheres are mostly cancer stem cells.
Therefore, the data shows that CSCs are resistant to acidic pH. On the other hand, when
MDA_MD-231 cells were cultured in a 2D culture system the cell number decreased
while the marker expressions increased in pH 6.8. The majority of the cells that are
cultured in 2D are cancer cells and a few percentages of them are cancer stem cells. The
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reduction in cell number shows the sensitivity of cancer cells to pH 6.8 and the increase
in expressions shows the resistance of breast cancer stem cells to pH reduction. On the
other hand, normal breast epithelial cells had higher level of reduction in both cell
number and markers expression in 2D and 3D cultures compared to cancer cells. The
results show that CSCs are more resistant to acidic pH compared to cancer cells and
normal cells.

2.3. Results and Discussion for Matrix Shape Experiment
In this study, we investigated the effect of micropatterned PEGDA with different shapes,
on the maintenance of breast CSCs encapsulated in PEGDA and incubated for 9 days in
CSC medium. Fluorescent Imaging, qRT-PCR, and DNA Content measurements have
been used in order to determine the differences between breast CSC maintenance and
behavior in different microshaped PEGDA.

2.3.1. Comparison of Sphere Formation of Tumor Cells Encapsulated in
Micropatterned PEGDA Gels in Fluorescent Images
Figure 2.9. Illustrates the effect of micropatterns including circle with 50 µm diameter,
square (50 µm*50 µm), rectangular (50 µm*150 µm), and rectangular (50 µm*250 µm),
on the sphere formation of cells, encapsulated in PEGDA gel. Figure 2.9. (a) is the
schematic pictures while Figure 2.9. (b) is the fluorescent images. Each arrow shows an
individual 3D micropattern (orange), corresponded to the micropattern in fluorescent
images, made of PEGDA located on the surface of a substrate (gray) which is made of
PEGDA with higher stiffness.
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Figure 2.8 Comparison of CD44, and ABCG2 expressions of the cells in CSC medium
with pH 7.4 and pH 6.8. Illustrate the effect of pH on the CD44 (b,d), and ABCG2 (a,c),
marker fold expressions of MDA-MB-123 and MCF10a cells cultured for 9 days in CSC
medium with pH 7.4 and pH 6.8.
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By florescent imaging and then shape analysis it was found out that cancer stem cells
still try to make the tumors in spherical shape regardless of the shape of the PEGDA,
which means that they try to have a minimum surface area for a given volume.

Micropatterned
PEGDA

Tumorsphere

Base layer

50 µm

50 µm

50 µm

50 µm

Figure 2.9 Comparison of tumor formation in micropatterned PEGDA gels. Illustrate of
schematic pictures (a) and fluorescent images (b) of the tumor size and distribution for
MDA_MB_123 tumor cells encapsulated in PEGDA gels with different micropatterns.
Each arrow shows an individual 3D micropattern (orange) made of PEGDA located on
the surface of a substrate (grey) which is made of PEGDA as well. The scale is 50 µm.
2.3.2. Comparison of Sphere Density, Sphere Diameter, and Cell Density of Tumorspheres
within PEGDA Gels Shaped with Different Micropatterns

The sphere density/ cell density for the cells encapsulated in PEGDA gels which were
shaped in circles with 50 µm diameter, squares (50 µm*50 µm), rectangulars (50
µm*150 µm), and rectangulars (50 µm*250 µm), incubated for 9 days in stem cell
culture medium are shown in Figures 2.10. (a).
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Figure 2.10 Comparison of tumoresphere density/ and sphere size of the cells
encapsulated in pmicroatterned PEGDA gels. Illustrates the effect of the micropatterns
on tumorsphere density/ cell density (a), and sphere size distribution (b) for MDA-MB123 tumor cells encapsulated in PEGDA gel and incubated in CSC medium for 9 days.
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The cell density of encapsulated MDA-MB-231 in patterned PEGDA was 1.6±0.15,
1.87±0.16, 2.60±0.18, 2.86±0.20 in circles, squares, rectangulars 75, rectangulars 150,
and rectangulars 250, respectively. Having different micropatterns did not have a
significant effect on the cell number of tumor cells encapsulated in PEGDA. The
tumorsphere density of MDA-MB-231 cells was 6256.33±397.86, 6700.53±459.09,
8866.67±711.63, 10121.15±942 in PEGDA gels patterned in circles, squares, rectangulars
75, rectangulars 150, and rectangulars 250, respectively. Results do not show any
considerable difference between groups.

2.3.3. Comparison of CD44, ABCG2, and TGF β Expressions of Tumor Cells
Encapsulated in Micropatterned PEGDA Gels
Figures 2.11. (a)- (c) shows the expressions of breast CSC markers CD44, ABCG2, and
TGF β for the encapsulated cells in micropatterned PEGDA for 9 days. CD44 is a cell
surface protein that has multiple functions in breast cancer development (Eibl et al.
1995). ABCG2 referred to as the Breast Cancer Resistance Protein (Allikmets et al. 1996).
This protein is critical in multi-drug resistance(Allikmets et al. 1996). TGF-β is a secreted
protein that mostly controls cellular proliferation and differentiation (Schoenhoff et al.
2009). It is highly

expressed by cancer cells and surrounding cells in cancer

microenvironment (Epstein et al. 2000).
After 9 days of incubation in CSC medium, CD44, ABCG2, and TGF β expression levels in
the cells encapsulated in patterned PEGDA were measured and no significant difference
between micropatterns have been observed. The results suggest that the shape of
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PEGDA gel did not have any effects on marker expression of breast cancer stem cells. To
wrap up, breast cancer stem cells form spherical tumors regardless of the shape of the
microenvironment suggesting that they try to have the minimum surface area for a
given volume.
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Figure 2.11 Comparison of CD44, ABCG2, and TGF β expressions of the tumor cells in
micropatterned PEGDA gels. Illustrates the effect of the micropatterns on ABCG2 (a),
TGF β (b), and CD44 (c), marker fold expressions of MDA-MB-123 cells encapsulated in
PEGDA
gel
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9
days
in
CSC
medium.
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Chapter 3:
Methods
3.1. PEGDA Synthesis
PEGDA was made by acrylation of hydroxyl end-groups of PEG with acrylate groups. In
that regard, acryloyl chloride was reacted with the hydroxyl groups of PEG at the end of
macromeres. Trimethylamine (TEA) was the reaction catalyst. At the beginning, PEG was
dried using azeotropic distillation from toluene in order to remove residual moisture.
The polymer was then dissolved in dried DCM and then cooled by the use of ice bath.
For the reaction, 5.6 mL of acryloyl chloride and 9.7 mL TEA dissolved in
dichloromethane (DCM), then were added to the reaction while constantly stirring. The
reaction continued for 12 hours under nitrogen flow.
After the reaction was finished, the solvent was removed through rotary evaporation
and then the rest was dissolved in anhydrous ethyl acetate. This was performed to
precipitate the by-product of the reaction which is trimethylamine hydrochloride salt.
Afterwards, vacuum distillation was used to remove ethyl acetate. Next the polymer
was dissolved in DCM and precipitated in cold ethyl ether two times. Next, the polymer
was

dissolved

in
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dimethylsulfoxide

(DMSO) and dialyzed against distilled deionized (DI) water in order to eliminate the byproducts. The PEGDA powder was freeze-dried and stored at -20°C.

3.2. Peptide Synthesis and Characterization
3.2.1. Preparing the Chromatographic Column and Amine Resin
In order to synthesize the peptide chains, 160 mg of amine resin (at room temperature)
was added into a 3 mL chromatographic column (CC). The bottom of the CC was capped
and 3 mL of dimethylformamide (DMF) was added to the column and the top of the CC
was capped. The CC was then vortexed and the resin was allowed to swell for 10
minutes. The CC was drained by uncapping and inserting the bottom tip into a vacuum,
trapping the resin in the filter. The bottom cap was replaced and the first amino acid
was prepared for addition.

3.2.2. Addition of an amino acid
The reaction for adding an amino acid must be performed in an oxygen-free
environment, in this case inside a nitrogen-gas filled pyramid (BRAND). For each
reaction, the following was placed inside the pyramid: the CC with dry resin, 160 µL
diisopropylcarbodiimide (DIC), 1 mmol of target amino acid and 2 mmol of
hydroxybenzotriazole (HoBT) dissolved in 6 mL of DMF, and 14 mg of
dimethylaminopyridine (DMAP) dissolved in 1 mL of DMF. Oxygen was vacuumed from
the pyramid and nitrogen was added until pyramid was fully inflated. The reaction was
performed as followed: First, the DMAP solution was added to the amino acid and HoBT
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solution. This solution was then added to the CC and 160 µL of DIC was pipetted into the
CC. The CC was capped tightly and shaken. The pyramid was opened and both ends of
the CC were wrapped with ParafilmTM and taped closed. The CC was then placed in a
shaker for a minimum of six hours for, unless adding the initial amino acid, then the CC
was placed in a shaker for at least 13 hours. After the waiting period, a Keizer test was
performed to determine if the amino acid was added correctly (color should stay
yellow).

3.2.3. Removal of the FMOC Group
In order to add an amino acid to the resin or an existing chain, the FMOC protecting
group must be cleaved of the last added amino acid. The resin was washed twice by
adding 6 mL of DMF, vortexing, and draining. Afterwards, 6 mL of 20% piperidine was
added, vortexed, and placed in a shaker for 12 minutes. Following the waiting period,
the piperidine was drained and the resin was washed twice again. Piperidine addition
was then repeated. After draining the piperidine, the resin was washed twice and a
Keizer test performed in order to determine if FMOC group was removed. If the Keizer
test turned blue, this means that there are unprotected amino acids and the reaction
can proceed. If the Keizer test turns yellow, then the FMOC group was not removed and
piperidine addition must be repeated.

3.2.4. Keiser Test
The Keiser test was used to determine the presence of unprotected amino acids. A small
amount of resin/DMF was extracted from the CC and added to a miniature CC. The DMF
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was drained and 1 mL of dichloromethane was added to the mini CC and then drained.
The following reagents were added to the mini CC: 7 drops of Ninhydrin, 2 drops of
Phenol, and 2 drops of KCN. The solution was mixed with a pipette and transferred to a
1.5 mL Eppendorf tube. Leaving the cover open, the tube was covered with aluminum
foil and placed in a heating block, preheated to 110 °C for ten minutes. If the solution
turns blue, there are unprotected amino acids and the amino acid addition reaction can
proceed. If the Keizer test produces a yellow solution, then the amino acid is successfully
added.

3.2.5. Addition of additional amino acids
In order to add additional amino acids, the same three procedures were taken as
described above, beginning with Addition of an amino acid.
Following the addition of the last amino acid, depending on the desired application,
either the FMOC group was cleaved or also terminated with acrylic acid or capped with
acetic anhydride.

3.2.6. Cleaving the Resin from the Peptide
Following the completion of the addition of the last amino acid, the resin must be
cleaved from the peptide chain. First, 45 mL of ethyl ether is cooled in a 50 mL tube. The
cleaving solution was prepared and composed of 95% trifluoroacetic acid (TFA), 2.5%
tiisopropylsilane (TIPS), 2.5% deionized water. The resin is then washed twice with DCM,
draining with a vacuum and placing the CC in a 15 mL tube. The CC tube was gently
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tilted for 1 minute and then 3 mL of the cleaving solution was added. After the bubbling
had ceased, the top was capped and placed on its sign for 1 minute. Every 20 minutes,
the CC was gently tilted; then the resin was allowed to resettle to the bottom. After 6
hours, the cooled ether was placed under the CC. The CC was quickly drained into the
ether containing 50 mL tube. 3 mL of cleaving solution was added to the CC and repeat
steps above. After cleaving the resin twice, the 50 mL tube to cooled to – 20 C and held
overnight at this temperature in the freezer to further precipitate the peptide. The 50
mL tube was centrifuged for 10 minutes at 4000 RPM. The supernatant was decanted
and freeze dried until a free-flowing powder was formed.
The acrylamide-terminated (Ac) peptides were further purified by preparative HPLC on a
250 x 10 mm, 10 µm Xterra Prep RP18 column (Waters, Milford, MA) with a flow rate of
2 mL/min using a gradient 5- 95% MeCN in 0.1% aqueous TFA at detection wavelength
of 214 nm. The HPLC fraction was lyophilized and the product was characterized with a
Finnigan 4500 Electro Spray Ionization (ESI) spectrometer (Thermo Electron, Waltham,
MA). The peptides and their scrambled ones are written in Table 1:
Table 3.1 Peptides and their scrambled sequence.
Peptide

LIGRKK

IKLLI

VAPG

SPPRRARV

RGD

RYD

WQPPRARI

Scrambled KGIKRL

ILKLI

PGVA

APRPVSRR

RDG

RDY

RPQIPWAR

peptide
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3.3. Hydrogel Preparation and Modulus Measurement
To prepare hydrogels, PEGDA polymer crosslinked within an aqueous solution, using
ultraviolet initiated radical polymerization with 4-(2-hydroxyethoxy)phenyl-(2-hydroxy2-propyl) ketone photoinitiator (Irgacure 3959; CIBA, Tarrytown, NY). Ten mg of initiator
was dissolved in 1 mL PBS at 50°C. A 13% PEGDA hydrogel precursor solution was
prepared by mixing 130 mg PEGDA macromer with 870 µL of the initiator solution. The
hydrogel precursor solution was filtered with 0.45 µm filter and degassed, then
transferred to a Teflon mold, covered with a piece of glass and sealed using clips. The
solution and irradiated with Omnicure Series 1500 UV light for 15 seconds. Following
crosslinking, the elastic modulus of the hydrogel was determined. Disc shape gel
samples were cut by an 8 mm cork-borer and were put in PBS for 24 hour at 37°C to
swell. The samples were then loaded onto the Pentier plate of a rheometer (TA
Instruments, New Castle, DE) and uniaxial compressive force at a displacement rate of
7.5 µm/s was used. The slope of the linear fit to the stress-strain curve for 5-10% strain
was taken as the elastic modulus of the hydrogel.

3.4. Cell Culture and Encapsulation in the Hydrogel
MDA-MB-123 human breast cancer cells were cultured in RPMI-1640 medium with 10%
FBS ,100 U/ml penicillin, and 100 mg/ml streptomycin under 5% CO2 at 37°C. Cells were
harvested by trypsin and suspended in 1640 after reaching 70% confluency. Cell density
was determined using a hemocytometer and Trypan blue assay. The cell density was
adjusted to 1.0x106 cells/mL. Then peptides were added to the hydrogel solution and
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the mixture was sterilized using a 4.5 µm filter. Afterwards, 1 million /ml cells were
added to the hydrogel precursor solution (13 wt%) and mixed softly. The cell-suspended
hydrogel precursor solution was added to a Teflon mold, covered with glass, and
crosslinked using UV (Omnicure Series 1500 Standard Filter) for 1 minutes. Following
crosslinking, the gel was cut and incubated in CSC medium consists of DMEM-F12
supplemented with 5 mg/ml insulin, 40 ng/ml bFGF, 20 ng/ml EGF, 5% horse serum, 100
U/ml penicillin, and 100 mg/ml streptomycin on ultra-low attachment tissue culture
plates for 9 days under 5% CO2 at 37°C .

3.5. PH Adjustment at 6.8
The following steps were used to incubate encapsulated cancer cells in CSC medium
with PH 6.8. First the PH of CSC media was reduced from 7.4 to 6.8 by using 1 molar HCl.
Then, the media was filtered with 0.1 µm filter and kept in an incubator for 2 days to
ensure the PH remains at 6.8. For the experiment, samples were kept in CSC media with
PH 6.8 in ultra-low
attachment tissue culture plates for 9 days and the media was changed every 24 hours.

3.6. Micropatterning
To encapsulate MDA-MB-231 cancer cells in a micropatterned gel. First, 50 μl of the
PEGDA precursor solution (25 wt%) were added to a glass slide. The edges of the glass
slide were covered with an adhesive tape to control gel thickness. Then the solution was
covered with a glass cover slip and kept under UV light for 8 min. After the gel was
formed, the glass slide edges were covered with another layer of adhesive tape in order
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to make a mold and 40 μl of the hydrogel precursor solution with cells was added on top
of the previous gel layer. Next, the UV mask was transferred at the top and then the
cell-hydrogel solution were places under UV light for 5 mins. The UV masks ( in different
shapes including circle, square, and rectangles) were designed with AutoCAD software
(AutoCAD 2010, Autodesk, San Rafael, CA) and printed on a transparent sheet. After the
gel was formed, it was washed with PBS to remove any remain material. Then the twolayer micropatterned gel was transferred to an ultra-low attachment tissue culture
plates and incubated in CSC medium for 9 days under 5% CO2 at 37°C.

3.7. Fluorescent Imaging
First samples (gel pieces) were removed from CSC medium and washed with PBS two
times. Then samples were fixed with 4% formaldehyde for 24 hours. Next, samples were
washed with PBS three times and then cells were permeabilized with PBS having 0.1%
Triton X-100 for 5 minutes. Samples again washed with PBS three times and then
incubated with Alexa 488 phalloidin (1:200 dilution) for 25 mins to stain cell s’ nucleus.
Afterwards, samples were washed with PBS six times; each time for 10 mins. Next, cells
were incubated with DAPI (1:5000 dilution) to stain actin filaments of the cells
‘cytoskeleton. Then samples were washed with PBS six times, each time for 10 mins.
Prepared samples were imaged with a Nikon Eclipse Ti-e inverted fluorescent
microscope.
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3.8.

Determination of Tumorsphere Number and Size

Fluorescent imaged were derived in to small sections and sphere size and density was
measured by using Image J software.

3.9. DNA Extraction from PEGDA Hydrogel and Cell Number Measurement
In order to extract the DNA from cells encapsulated in PEGDA hydrogel, the hydrogel
needs to be degraded or destroyed. In that regard, first hydrogel samples were
submerged within liquid nitrogen. The gel samples were then pulverized using a mortar
and pestle until resembling a fine powder. The samples must be well pulverized and
liquid nitrogen was intermittently poured on the samples to keep them cold. Following
pulverization, the samples were added to 0.1 mL of lysis buffer (0.2% triton+10 mM Tris)
consists of inside a 2 mL glass homogenizer and were homogenized with lysis buffer
until well incorporated. The samples were then transferred to a 1.5 mL centrifuge tube
and centrifuged for 5 minutes at 12000 RPM in order to remove gel debris. Up to 100 µl
of supernatant was transferred to a sterile centrifuge tube. To measure the cell number,
the double stranded DNA (dsDNA) content using a Quant-it PicoGreen assay was
performed. Regarding that, 100 µl of working solution was added to 100 µL of the cell
lysate and incubated for 4 min at room temreture. The fluorescence of the solution was
measured with a plate reader (Synergy HT, Bio-Tek, Winooski, VT) at emission and
excitation wavelength of 485 and 528 nm, respectively. Flourescent intensities were
linked to cell numbers using a calibration curve made with cells of known concentration
ranging from zero to 10 million cells/ml.
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3.10. RNA Extraction from PEGDA Hydrogel and qRT-PCR
In order to extract the RNA from cells encapsulated in PEGDA, the hydrogel needs to be
destroyed. This was done by first submerging hydrogel samples within liquid nitrogen.
The gel samples were then pulverized using a mortar and pestle until resembling a fine
powder. The samples must be well pulverized and liquid nitrogen was intermittently
poured on the samples to keep them cold. Following pulverization, the samples were
added to 1 mL of TRIzol® inside a 2 mL glass homogenizer. The sample was homogenized
with TRIzol® until well incorporated. Sample was then transferred to a 1.5 mL centrifuge
tube and centrifuged for 6 minutes at 9000 RPM in order to remove gel debris. Up to 1
mL of supernatant was transferred to a sterile centrifuge tube. Up to 200 µL of
chloroform was added to the sample (1:5 chloroform:sample) and shaken for 30
seconds. The sample was put on ice for 3 minutes and then centrifuged for 10 minutes
at 13200 rpm. Following centrifugation, the supernatant was transferred to a new,
sterile centrifuge tube. An equal amount of ethanol (95-100%) was added to the
supernatant and pipetted to mix. The sample RNA solution was then transferred to a
pink QIAGEN RNeasy spin column, centrifuged for 30 seconds at 9000 rpm, and flow
through discarded. Next, 700 µL of RW1 Buffer (QIAGEN) was added to the column, the
column was then centrifuged, and flow through discarded. The sample was then washed
twice by adding 500 µL of RPE Buffer (QIAGEN, diluted according to the bottle),
centrifuging, discarding the flow through and then repeating a second time. After
washing the sample twice, the collection tube was then replaced with a sterile 1.5 mL
centrifuge tube. In order to dissolve the RNA, 30-50 µL of RNAse free water was added
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to the sample and allowed to site for 1 minute. The sample was then centrifuged for 1
minute at the highest rpm. Flow through, containing the RNA, was then stored at -80 °C
for further use in qRT-PCR.
Following TRIzol RNA extraction as described above, by using Nano drop, RNA
concentration of samples was equalized. Purified RNA with equal amount for all samples
was reverse transcribed to cDNA by using SuperScript II Reverse Transcriptase
(Invitrogen) with random primers. The cDNA was amplified using quantitative real time
polymerase chain reaction (qRT-PCR) with the appropriate gene specific primers. The
differential expression of CSC markers: CD44, ABCG2, and TGFβ genes with SYBR green
RealMasterMix (Eppendorf, Hamburg, Germany) using Bio-Rad iCycler PCR system (BioRad, Hercules, CA) was measred. GAPDH gene was used as an internal control. The gene
specific primer sequences that were used are as following. Human GAPDH: forward 5’GAGTCAACGGATTTG GTCGT-3’, reverse 5’-TTGATTTTGGAGGGATCTCG-3’,
human

CD44:

forward

5’-GGCTTTCAATAGCACCTTGC-3’,

reverse

5’-

ACACCCCTGTGTTGTTTGCT-3’, human ABCG2: forward 5’-CACCTTATTGGCCTCAGGAA-3’,
reverse

5’

CCTGCTTGGAAGGCTCTATG-3’,

human

TGF-β:

forward

5’-

CCGGAGGTGATTTCCATCTA-3’, reverse 5’-CTCCATTGCTGAGACGTCAA-3’.

3.11. Statistical Analysis
Data were reported as means ± standard deviation. A two-tailed Student’s t-test was
used to determine significant differences between groups. A value of p<0.05 was
considered

statistically
62

significant.

Conclusion
We have used a 3D PEGDA culture model and demonstrated that cell binding peptides
such as RGD, RYD, IKLLI, LIGRKK, VAPG, WQPPRARI, and SPPRRARV cross-linked to the
hydrogel can reduce the ability of breast CSCs to form tumorspheres in PEGDA. Among
peptides RGD, RYD and WQPPRARI were the most active peptides in reducing the
sphere formation of breast cancer stem cells. It has also been shown that, breast
cancer stem cells are more resistance to acidic pH compared to breast cancer cells and
normal breast epithelial cells. Also, breast cancer stem cells formed spherical tumors in
micropatterned PEGDA, regardless of the shape of the micropatterns and tried to have
minimum

surface

area

for
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a

given

volume
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